The terms of reference and profiles shown below have been approved by the Ph. Eur. Commission at its 163rd session (March 2019). Experts shall fulfil the profile described. It is also expected that experts once appointed by the Ph. Eur. Commission will be available to attend meetings and are prepared to draft and/or verify monographs and general chapters and when required in the profile, have access to a laboratory for experimental verifications.

Each group of experts and working party will advise the Commission and other groups of experts and working parties where relevant, according to their expertise and contribute to the maintenance of the relevant technical guide where appropriate.

In the context of this document, the term “regulatory authority” encompasses OMCLs, licensing authorities, NPAs and/or inspectorates.

**Pro memoria:**

- Candidates from Ph. Eur. member states: Applications are to be submitted to your national pharmacopoeia authority (NPA).
- Candidates from non Ph. Eur. member states: Applications are to be submitted to the EDQM via the Helpdesk (please consult the following webpage https://www.edqm.eu/en/join-network for more information)

## INDEX:

<table>
<thead>
<tr>
<th>Group of Experts No.</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group of Experts No. 1 (Microbiology)</td>
<td>4</td>
</tr>
<tr>
<td>Group of Experts No. 6 (Biological and Biotechnological products)</td>
<td>4</td>
</tr>
<tr>
<td>Group of Experts No. 6B (Human Plasma and Plasma Products)</td>
<td>5</td>
</tr>
<tr>
<td>Group of Experts No. 7 (Antibiotics)</td>
<td>5</td>
</tr>
<tr>
<td>Group of experts No. 9 (Inorganic Chemistry)</td>
<td>6</td>
</tr>
<tr>
<td>Group of Experts No. 9G (Medicinal Gases)</td>
<td>6</td>
</tr>
<tr>
<td>Group of Experts No. 10A/B/C/D (Organic chemistry – synthetic and semi-synthetic products)</td>
<td>7</td>
</tr>
<tr>
<td>Group of Experts No. 11 (Organic chemistry – natural, semi-synthetic and synthetic products)</td>
<td>7</td>
</tr>
<tr>
<td>Group of Experts No. 12 (Dosage forms and pharmaceutical technical procedures)</td>
<td>7</td>
</tr>
<tr>
<td>Group of Experts No. 13A/B (Herbal Drugs and Herbal Drug Preparations)</td>
<td>8</td>
</tr>
<tr>
<td>Group of Experts No. 13H (Fatty oils and derivatives, polymers)</td>
<td>8</td>
</tr>
<tr>
<td>Group of Experts No. 14 (Radiopharmaceutical Preparations)</td>
<td>9</td>
</tr>
<tr>
<td>Group of Experts No. 15 (Human Vaccines and Sera)</td>
<td>9</td>
</tr>
<tr>
<td>Group of Experts No. 15V (Veterinary Vaccines and Sera)</td>
<td>10</td>
</tr>
<tr>
<td>Group of Experts No. 16 (Plastic materials, plastic containers and closures)</td>
<td>10</td>
</tr>
<tr>
<td>Group of Experts 17 (Medicinal products containing chemically defined active substances)</td>
<td>10</td>
</tr>
<tr>
<td>Group of Experts P4</td>
<td>11</td>
</tr>
<tr>
<td>ALG Working Party (Allergens)</td>
<td>11</td>
</tr>
<tr>
<td>BET Working Party (Bacterial Endotoxin Test)</td>
<td>12</td>
</tr>
<tr>
<td>BSR Working Party (Bovine serum)</td>
<td>12</td>
</tr>
<tr>
<td>CE Working Party (Capillary Electrophoresis)</td>
<td>13</td>
</tr>
<tr>
<td>CEL Working Party (Cellulose)</td>
<td>13</td>
</tr>
<tr>
<td>CND Working Party (Conductivity)</td>
<td>13</td>
</tr>
<tr>
<td>COL Working Party (Colour determination)</td>
<td>14</td>
</tr>
<tr>
<td>CRB Working Party (Carbohydrates)</td>
<td>14</td>
</tr>
<tr>
<td>No.</td>
<td>Working Party</td>
</tr>
<tr>
<td>-----</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>1</td>
<td>CST Working Party (Chromatographic separation techniques)</td>
</tr>
<tr>
<td>2</td>
<td>CTP Working Party (Cell Therapy Products)</td>
</tr>
<tr>
<td>3</td>
<td>DIA Working party (Dialysis)</td>
</tr>
<tr>
<td>4</td>
<td>EXP Working Party (Excipient performance)</td>
</tr>
<tr>
<td>5</td>
<td>EXT Working Party (Extracts)</td>
</tr>
<tr>
<td>6</td>
<td>GEL Working Party (Gelatin)</td>
</tr>
<tr>
<td>7</td>
<td>GLS Working Party (Glass Containers)</td>
</tr>
<tr>
<td>8</td>
<td>GTP Working Party (Gene Therapy Products)</td>
</tr>
<tr>
<td>9</td>
<td>HM Working Party (Heavy metals)</td>
</tr>
<tr>
<td>10</td>
<td>HMM Working Party (Homoeopathic Manufacturing Methods)</td>
</tr>
<tr>
<td>11</td>
<td>HOM Working Party (Homoeopathic Raw Materials and Stocks)</td>
</tr>
<tr>
<td>12</td>
<td>ICP Working Party (Inductively-Coupled Plasma)</td>
</tr>
<tr>
<td>13</td>
<td>INH Working Party (Inhalations)</td>
</tr>
<tr>
<td>14</td>
<td>LEC Working Party (Lecithins)</td>
</tr>
<tr>
<td>15</td>
<td>MAB Working Party (Monoclonal Antibodies)</td>
</tr>
<tr>
<td>16</td>
<td>MG Working Party (General methods)</td>
</tr>
<tr>
<td>17</td>
<td>MYC Working Party (Mycoplasma)</td>
</tr>
<tr>
<td>18</td>
<td>NBC Working Party (Non-Biological Complex Drugs)</td>
</tr>
<tr>
<td>19</td>
<td>P4BIO Working Party (P4 Bio)</td>
</tr>
<tr>
<td>20</td>
<td>PA Working Party (Pyrrolizidine alkaloids)</td>
</tr>
<tr>
<td>21</td>
<td>PaedF Working Party (European Paediatric Formulary)</td>
</tr>
<tr>
<td>22</td>
<td>PAT Working Party (Process Analytical Technology)</td>
</tr>
<tr>
<td>23</td>
<td>POW Working Party (Powder Characterisation)</td>
</tr>
<tr>
<td>24</td>
<td>PRP Working Party (Precursors for Radiopharmaceutical Preparations)</td>
</tr>
<tr>
<td>25</td>
<td>PST Working Party (Pesticide Residues)</td>
</tr>
<tr>
<td>26</td>
<td>SDA Working Party (Spectroscopy and Data Analysis)</td>
</tr>
<tr>
<td>27</td>
<td>SIT Working Party (Second identification test)</td>
</tr>
<tr>
<td>28</td>
<td>ST Working Party (Standard Terms)</td>
</tr>
<tr>
<td>29</td>
<td>SUT Working Party (Sutures)</td>
</tr>
<tr>
<td>30</td>
<td>TCM Working Party (Traditional Chinese Medicines)</td>
</tr>
<tr>
<td>31</td>
<td>VIT Working Party (Vitamins)</td>
</tr>
<tr>
<td>32</td>
<td>WAT Working Party (Water)</td>
</tr>
</tbody>
</table>
Group of Experts No. 1 (Microbiology)

Terms of reference

• Drafting and revision of general chapters in the field of microbiology
• Advising the Commission on questions related to microbiological quality, including quality attributes in monographs drafted by other groups of experts and working parties
• International harmonisation of general chapters in the field of microbiology
• Drafting and revision of general chapters in the field of alternative microbiological methods (the so-called “rapid” methods)
• Assessment of proposed examples in view of their inclusion in document: “Examples of validation protocols for alternative microbiological methods according to chapter 5.1.6”, to be published on the EDQM website.

Profile for experts

• Current expertise in microbiological analytical methods, related to quality control of active substances, excipients and medicinal products and in development of control methods
• Several years of experience in one or more of the following fields:
  o Microbiological quality control in a pharmaceutical manufacturing setting, in a hospital environment or in an independent testing laboratory
  o Market surveillance of microbiological quality in a regulatory authority
  o Assessment of the relevant parts of applications for marketing authorisation
  o Development of microbiological control methods in a research and development environment

Profile for ad-hoc specialists on alternative microbiological methods (please indicate this field of expertise on the nomination form, if applicable)

• Current expertise in microbiological analytical methods, related to quality control of active substances, excipients and medicinal products and in development of control methods
• Several years of experience in one or more of the following fields:
  o Validation of alternative microbiological methods in a pharmaceutical manufacturing setting, in a hospital environment or in an independent testing laboratory
  o Market surveillance of microbiological quality in a regulatory authority using alternative microbiological methods
  o Assessment of the relevant parts of applications for marketing authorisation
  o Development of alternative microbiological control methods in a research and development environment

Group of Experts No. 6 (Biological and Biotechnological products)

Terms of reference

• Drafting and revision of texts in the field of biological products, biotechnological products, synthetic peptides including glycan mapping
• International harmonisation of general chapters in the field of biological products

Profile for experts

• Current expertise in quality control of biological products, biotechnological products, peptides
• Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of test methods and drafting of texts
• Several years of experience in one or more of the following fields:
Quality control of biological products, biotechnological products, peptides in a pharmaceutical manufacturing setting

Quality control in a regulatory authority

Quality control of biological or biotechnological products in an independent testing laboratory

Development of methods for control of biological products, biotechnological products, peptides in a research and development environment

Method development and verification in a regulatory authority

Assessment of the relevant parts of application for marketing authorisation of biological and biotechnological products within a medicines agency

Profile for glycan mapping ad-hoc specialists (please indicate this field of expertise on the nomination form, if applicable)

- Current expertise in pharmaceutical analytical methods, related to quality control of glycoproteins and in development of control methods
- Several years of experience in one or more of the following fields:
  - Quality control of glycoproteins in a pharmaceutical manufacturing setting
  - Market surveillance of quality of glycoproteins in a regulatory authority
  - Pharmaceutical quality control of glycoproteins in an independent testing laboratory
  - Assessment of the relevant parts of application for marketing authorisation of biological and biotechnological products within a medicines agency
  - Method development and verification in a regulatory authority
  - Development of control methods for glycoproteins in a research and development environment

Group of Experts No. 6B (Human Plasma and Plasma Products)

Terms of reference

- Drafting and revision of texts in the field of blood products

Profile for experts

- Current expertise in the field of blood products, notably related to quality control of and development of control methods
- Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs, **Essential**: Active involvement in laboratory verification of test methods and drafting of texts
- Several years of experience in one or more of the following fields:
  - Quality control of blood products in a pharmaceutical or bulk manufacturing setting
  - Batch release or market surveillance of Human Blood, Plasma and Plasma Products in a regulatory authority
  - Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  - Quality control of blood products in an independent testing laboratory
  - Method development and verification in a regulatory authority
  - Development of methods for control Human Plasma and Plasma Products in a research and development environment

Group of Experts No. 7 (Antibiotics)

Terms of reference

- Drafting and revision of texts in the field of antibiotic active substances
- Provision of expertise in the field of antibiotics to Group 17 where relevant

Profile for experts

- Current expertise in the fields of antibiotics
• Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs, **Essential**: Active involvement in laboratory verification of test methods and drafting of texts

• Several years of experience in one or more of the following fields:
  
  o Quality control of antibiotics in a pharmaceutical manufacturing setting
  
  o Quality control of antibiotics in a bulk manufacturing setting
  
  o Quality control of antibiotics in a regulatory authority
  
  o Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  
  o Quality control of antibiotics in an independent testing laboratory
  
  o Development of methods for control of antibiotics in a research and development environment
  
  o Method development and verification in a regulatory authority

**Group of experts No. 9 (Inorganic Chemistry)**

*Terms of reference*

• Drafting and revision of monographs in the field of inorganic substances

• International harmonisation of monographs

*Profile for experts*

• Current expertise in pharmaceutical analytical methods, related to quality control of inorganic substances and in development of control methods

• Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs, for example ICP and/or AAS. **Essential**: Active involvement in laboratory verification of test methods and drafting of texts.

• Several years of experience in one or more of the following fields:
  
  o Quality control of inorganic substances in a pharmaceutical or bulk manufacturing setting
  
  o Market surveillance of quality in a regulatory authority
  
  o Pharmaceutical quality control in an independent testing laboratory
  
  o Development of methods for control of inorganic substances in a research and development environment
  
  o Method development and verification in a regulatory authority

**Group of Experts No. 9G (Medicinal Gases)**

*Terms of reference*

• Drafting and revision of texts in the field of medicinal gases

*Profile for experts*

• Current expertise in the field of medicinal gases

• Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs, **Essential**: Active involvement in laboratory verification of test methods and drafting of texts

• Several years of experience in one or more of the following fields:
  
  o Quality control of medicinal gases in a pharmaceutical manufacturing, hospital or industrial setting
  
  o Quality control in a regulatory authority
  
  o Development of methods for control of medicinal gases in a research and development environment
Group of Experts No. 10A/B/C/D (Organic chemistry – synthetic and semi-synthetic products)

Terms of reference

• Drafting and revision of monographs in the field of synthetic and semi-synthetic organic substances
• If needed, provide expertise in the field of organic chemistry to Group 17

Profile for experts

• Current expertise in pharmaceutical analytical methods, related to quality control of synthetic and semi-synthetic organic substances and in development of control methods
• Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of test methods and drafting of texts.
• Several years of experience in one or more of the following fields:
  o Quality control in a pharmaceutical manufacturing setting
  o Quality control of synthetic and semi-synthetic organic products in a bulk manufacturing setting
  o Market surveillance of quality in a regulatory authority
  o Pharmaceutical quality control of synthetic and semi-synthetic organic substances, in an independent testing laboratory
  o Development of methods for control of synthetic and semi-synthetic organic substances in a research and development environment
  o Group 10D: development of control methods for amino-acids
  o Method development and verification in a regulatory authority

Group of Experts No. 11 (Organic chemistry – natural, semi-synthetic and synthetic products)

Terms of reference

• Drafting and revision of monographs in the field of natural, semi-synthetic and synthetic organic substances
• Provision of expertise in the field of organic chemistry to the Group 17 where relevant

Profile for experts

• Current expertise in pharmaceutical analytical methods, related to quality control of natural, semi-synthetic and synthetic organic substances, and in development of control methods
• Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of test methods and drafting of texts.
• Several years of experience in one or more of the following fields:
  o Quality control in a pharmaceutical manufacturing setting
  o Quality control of natural, semi-synthetic and synthetic organic substances in a bulk manufacturing setting
  o Market surveillance of quality in a regulatory authority
  o Pharmaceutical quality control in an independent testing laboratory
  o Development of methods for control of natural, semi-synthetic and synthetic organic substances in a research and development environment
  o Method development and verification in a regulatory authority

Group of Experts No. 12 (Dosage forms and pharmaceutical technical procedures)

Terms of reference

• Drafting and revision of dosage form monographs and pharmaceutical technical procedures
• Maintenance of dosage form related International Harmonisation topics such as:
  o Uniformity of dosage units
  o Dissolution
Profile for experts

- Current expertise in pharmaceutical development and control methods applied during manufacture and to finished pharmaceutical preparations, in the relevant specialities defined in the terms of reference
- Several years of experience in one or more of the following fields:
  - Development and quality control of pharmaceutical preparations in an industrial setting
  - Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  - Development of methods for testing of pharmaceutical preparations in a research and development environment
  - Method development and verification in a regulatory authority

Group of Experts No. 13A/B (Herbal Drugs and Herbal Drug Preparations)

Terms of reference

- Drafting and revision of texts in the field of herbal drugs and herbal drug preparations

Profile for experts

- Current expertise in pharmaceutical analytical methods, related to quality control in the relevant specialities defined in the terms of reference
- Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of test methods and drafting of texts.
- Several years of experience in one or more of the following fields:
  - Quality control of herbal drugs and herbal drug preparations in a pharmaceutical manufacturing or bulk manufacturing setting
  - Market surveillance of quality of herbals in a regulatory authority
  - Assessment of the relevant parts of applications for marketing authorisation of herbal medicinal products within a medicines agency
  - Pharmaceutical quality control of herbal drugs and herbal drug preparations in an independent testing laboratory
  - Development of methods for control of herbal drugs in a research and development environment
  - Method development and verification in a regulatory authority

Group of Experts No. 13H (Fatty oils and derivatives, polymers)

Terms of reference

- Drafting and revision of texts in the field of:
  - surfactants
  - fatty oils, fats and waxes
  - fatty acids, fatty alcohols and their esters/ethers
  - macrogols, macrogol derivatives and other polymers (i.e. carbomers)
  - Paraffins
  - International Harmonisation of the relevant monographs

Profile for experts

- Current expertise in pharmaceutical analytical methods, related to quality control in the relevant specialities defined in the terms of reference
- Member of a regulatory authority, universities or the pharmaceutical/chemical industries
• Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs,
  **Essential**: Active involvement in laboratory verification of test methods and drafting of texts
• Several years of experience in one or more of the following fields:
  o Quality control in a pharmaceutical manufacturing setting
  o Quality control of fats etc. in a bulk manufacturing setting
  o Market surveillance of quality in a regulatory authority
  o Pharmaceutical quality control of fats etc. in an independent testing laboratory
  o Development of methods for control of fats etc. in a research and development environment
  o Method development and verification in a regulatory authority

**Group of Experts No. 14 (Radiopharmaceutical Preparations)**

**Terms of reference**

• Drafting and revision of texts in the field of radiopharmaceutical preparations

**Profile for experts**

• Current expertise in pharmaceutical analytical methods, related to quality control of radiopharmaceutical preparations and in development of control methods
• Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs, **Essential**: Active involvement in laboratory verification of test methods and drafting of texts
• Several years of experience in one or more of the following fields:
  o Quality control of radiopharmaceutical preparations in a pharmaceutical manufacturing setting or in a hospital
  o Market surveillance of quality of radiopharmaceutical preparations in a regulatory authority
  o Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  o Pharmaceutical quality control of radiopharmaceutical preparations in an independent testing laboratory
  o Method development and verification in a regulatory authority

**Group of Experts No. 15 (Human Vaccines and Sera)**

**Terms of reference**

• Drafting and revision of texts in the field of vaccines and sera for human use
• Drafting and revision of monographs in the field of botulinum toxins

**Profile for experts**

• Current expertise in analytical methods, related to quality control of vaccines and sera for human use and in development of control methods
• Several years of experience in one or more of the following fields:
  o Quality control of vaccines and sera for human use in a pharmaceutical manufacturing setting
  o Batch release and market surveillance of quality of vaccines and sera for human use in a regulatory authority
  o Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  o Quality control of vaccines and sera for human use in an independent testing laboratory

**Profile for botulinum toxins ad hoc specialists (please indicate this field of expertise on the nomination form, if applicable)**

• Current expertise in analytical methods for botulinum toxins and in development of control methods
• Several years of experience in one or more of the following fields:
Group of Experts No. 15V (Veterinary Vaccines and Sera)

Terms of reference
• Drafting and revision of texts in the field of immunological veterinary medicinal products (IVMP)

Profile for experts
• Current expertise in suitable standards for IVMP, in methods related to quality control of these products and in development of control methods
• Several years of experience in one or more of the following fields:
  o Quality control of IVMP in a regulatory authority
  o Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  o Batch release and market surveillance of quality in a regulatory authority
  o Development of methods for control of IVMP in a research and development environment
• Industry representatives are normally not appointed to Group of Experts No. 15V. They may be invited to contribute to elaboration of texts during hearings organised on a case-by-case basis by the Secretariat.

Group of Experts No. 16 (Plastic materials, plastic containers and closures)

Terms of reference
• Drafting and revision of texts in the field of plastic materials, plastic containers and closures

Profile for experts
• Current expertise in the fields covered by the terms of reference
• Access to laboratory facilities for verification and validation of methods proposed for inclusion in texts, Essential: Active involvement in laboratory verification of test methods and drafting of texts
• Several years of experience in one or more of the following fields:
  o Quality control of plastic materials, plastic containers and closures in a pharmaceutical manufacturing setting
  o Quality control of plastic materials, plastic containers and closures in a regulatory authority
  o Quality control of plastic materials, plastic containers and closures in an independent testing laboratory
  o Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  o Method development and verification in a regulatory authority

Group of Experts 17 (Medicinal products containing chemically defined active substances)

Terms of reference
• Drafting and revision of monographs on medicinal products containing chemically defined active substances
• Drafting of monographs on active substances contained in these medicinal products if the monographs are being elaborated in parallel and if deemed appropriate;
• Drafting and maintenance of the technical guide for the elaboration of monographs on medicinal products containing chemically defined active substances
• Provision of expertise to other groups (such as Group P4) where relevant

Profile for experts

• Current expertise in pharmaceutical analytical methods, related to quality control of medicinal products containing chemically defined active substances and in development of such methods

• Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of test methods and drafting of texts.

• Several years of experience in one or more of the following fields:
  o Development and verification of test methods
  o Quality control or development of medicinal products containing chemically defined active substances
  o Market surveillance testing
  o Assessment of the relevant parts of applications for marketing authorisation within a medicines agency

Group of Experts P4

Terms of reference

• Drafting and revision of monographs in the field of single-source active substances, excipients and medicinal products with chemically defined active substances

Profile for experts

• Current expertise in pharmaceutical analytical methods, related to quality control of active substances, excipients and medicinal products (with chemically defined active substances), and in development of control methods

• Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs or access to licensing files, Essential: Active involvement in laboratory verification of test methods and drafting of texts.

• Several years of experience in one or more of the following fields:
  o Assessment of the relevant parts of applications for marketing authorisation
  o Market surveillance studies in a regulatory authority
  o Method development and verification in a regulatory authority

• Group P4 is restricted to regulators from Ph. Eur. Member states however industry representatives may be invited to contribute by submission of data and interaction with the group via the Secretariat

ALG Working Party (Allergens)

Objective

• Drafting and revision of texts in the field of allergen products

Profile for experts

• Current expertise in pharmaceutical analytical methods, related to quality control of allergens and in development of control methods

• Several years of experience in one or more of the following fields:
  o Quality control of allergen products in a pharmaceutical manufacturing setting
  o Market surveillance of quality of allergen products in a regulatory authority
  o Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  o Pharmaceutical quality control of allergen products in an independent testing laboratory
  o Development of methods for control of allergens in a research and development environment
BET Working Party (Bacterial Endotoxin Test)

Terms of reference

• Drafting and revision of general chapters in the field of bacterial endotoxins
• Advising the Commission and expert groups on appropriate methods for the detection of bacterial endotoxins or pyrogens in substances for pharmaceutical use or pharmaceutical preparations.
• Drafting and revision of general chapters in the field of the monocyte activation tests (MAT)
• International Harmonisation of the relevant texts

Profile for experts

• Several years of experience in one or more of the following fields:
  o Quality control of parenteral preparations, active substances and/or excipients in a pharmaceutical manufacturing setting
  o Market surveillance of quality in a regulatory authority
  o Pharmaceutical quality control in an independent testing laboratory
  o Development of control methods for bacterial endotoxin test in a research and development environment
  o Access to laboratory facilities for verification and validation of methods proposed

Profile for MAT ad hoc specialists (please indicate this field of expertise on the nomination form, if applicable)

• Current expertise in practical application of the monocyte activation test
• Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs,
• Several years of experience in one or more of the following fields:
  o Quality control of parenteral preparations, active substances and/or excipients in a pharmaceutical manufacturing setting
  o Market surveillance of quality in a regulatory authority
  o Pharmaceutical quality control in an independent testing laboratory
  o Development of control methods for monocyte activation test in a research and development environment
  o Method development and verification in a regulatory authority

BSR Working Party (Bovine serum)

Terms of reference

• Maintenance of the monograph Bovine serum (2262)
• Drafting and revision of other texts pertaining to bovine sera as appropriate

Profile for experts

• Current expertise in analytical methods related to quality control of bovine sera and in development of control methods
• Several years of experience in one or more of the following fields:
  o Quality control of bovine serum in a pharmaceutical manufacturing setting
  o Market surveillance of quality in a regulatory authority
  o Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  o Pharmaceutical quality control in an independent testing laboratory
  o Development of methods for control of bovine serum in a research and development environment
CE Working Party (Capillary Electrophoresis)

Terms of reference

- Revision of the chapter 2.2.47 Capillary electrophoresis
- Advising the Commission on questions related to capillary electrophoresis in monographs drafted by other groups of experts and working parties
- International Harmonisation of the relevant texts

Profile for experts

- Current expertise in Capillary electrophoresis techniques
- Several years of experience in the following fields:
  - Quality control of active substances, excipients and medicinal products, using capillary electrophoresis techniques, in a pharmaceutical manufacturing setting, in a regulatory authority or in any other testing laboratory
  - Development of capillary electrophoresis methods for control of active substances, excipients and medicinal products in a research and development environment or at university
  - Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs Essential: Active involvement in laboratory verification of test methods and drafting of texts

CEL Working Party (Cellulose)

Terms of reference

- Drafting and revision of monographs on cellulose and cellulose derivatives
- International harmonisation of monographs on cellulose and cellulose derivatives

Profile for experts

- Current expertise in analytical methods for cellulose and cellulose derivatives and in development of control methods
- Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of test methods and drafting of texts.
- Several years of experience in one or more of the following fields:
  - Quality control of cellulose and cellulose derivatives in a pharmaceutical or other industrial manufacturing setting
  - Market surveillance of quality of cellulose and cellulose derivatives in a regulatory authority
  - Quality control of cellulose and cellulose derivatives in a regulatory authority
  - Development of control methods for cellulose and cellulose derivatives in a research and development environment
  - Method development and verification in a regulatory authority

CND Working Party (Conductivity)

Terms of reference

- International harmonisation of general chapter 2.2.38 Conductivity

Profile for experts

- Current expertise in conductivity measurement
- Several years of experience in one or more of the following fields:
  - Quality control using conductivity measurement in a pharmaceutical manufacturing setting
  - Market surveillance of quality using conductivity measurement in a regulatory authority
  - Conductivity measurement for pharmaceutical analysis in an independent testing laboratory
  - Conductivity measurement in a regulatory authority
Development of methods for conductivity measurement in a research and development environment

COL Working Party (Colour determination)

Terms of reference

- Drafting and revision of monographs and texts in the field of instrumental determination of colour (PDG item Q-07)
- Establishing correlation between measurement using Ph. Eur. Chapter 2.2.2 and the tristimulus type instruments

Profile for experts

Several years of experience in one or more of the following fields:

- Users: Expertise in the use of tristimulus-type of colour measuring instruments in the field of pharmaceutical development, quality control of pharmaceuticals, food, cosmetics or drinking water
- Instrument suppliers: Personnel involved in user-support for practical application of tristimulus-type instruments in the field of pharmaceutical development, quality control of pharmaceuticals, food, cosmetics or drinking water
- Experience in research or university teaching related to instrumental colour determination of liquids

CRB Working Party (Carbohydrates)

Terms of reference

- Drafting and revision of monographs in the field of carbohydrates
- International harmonisation of monographs

Profile for experts

- Current expertise in pharmaceutical analytical methods, related to quality control of carbohydrates and in development of control methods
- Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs, **Essential**: Active involvement in laboratory verification of test methods and drafting of texts.
- Several years of experience in one or more of the following fields:
  - Quality control in a pharmaceutical or bulk manufacturing setting
  - Market surveillance of quality in a regulatory authority
  - Pharmaceutical quality control in an independent testing laboratory
  - Development of control methods for carbohydrates in a research and development environment
  - Method development and verification in a regulatory authority

CST Working Party (Chromatographic separation techniques)

Terms of reference

- Revision of the chapter 2.2.46 Chromatographic separation techniques
- Revision of other chapters on chromatographic separation (e.g. 2.2.29, 2.2.30)
- International harmonisation of chapter 2.2.46 (PDG item G-20)
- Advising the Commission on questions related to chromatographic separation techniques in monographs drafted by other groups of experts and working parties
- Co-operation with other groups of experts and working parties which use chromatographic separation techniques where relevant
Profile for experts

- Current expertise in chromatographic separation techniques
- Several years of experience in one or more of the following fields:
  - Chromatographic quality control of active substances and/or excipients in a pharmaceutical manufacturing setting
  - Development of chromatographic methods for control of active substances, excipients and medicinal products in a research and development environment
  - Market surveillance of quality in a regulatory authority
  - Pharmaceutical quality control in an independent testing laboratory

CTP Working Party (Cell Therapy Products)

Terms of reference

- Revision of general chapter 2.7.29 Nucleated cell count and viability in order to update it with new automated technologies for cell enumeration (e.g. image cytometry)
- Revision of Ph. Eur. texts (monographs or chapters) where it might be necessary to account for chapter 5.2.12 Raw materials of biological origin for the production of cell-based and gene therapy medicinal products
- Evaluation of the need to revise the introductory statement of the monograph on parenteral preparations (0520) by adding cell-based preparations to the list of preparations to which the monograph does not necessarily apply, and if so, evaluation of the need for a general Ph. Eur. text dealing with cell-based preparations
- Drafting and revision of other texts in the field of cell therapy products

Profile for experts

- Current expertise in analytical methods related to the development and quality control of cell therapy products and/or tissue-engineered products and/or to the quality control of tissues for human use
- Several years of experience in one or more of the following fields:
  - Development of cell therapy products and/or tissue-engineered products
  - Quality control of cell therapy products and/or tissue-engineered products in a pharmaceutical manufacturing setting or in a hospital environment and/or microbiological control of tissues and organs used for human transplantation
  - Assessment of applications for marketing authorisation of cell therapy and/or tissue-engineered products
  - Market surveillance of the quality of cell therapy products, tissue-engineered products and/or tissues and organs used for human transplantation in a regulatory authority
  - Pharmaceutical quality control in an independent testing laboratory
  - Development of methods (e.g. microbiological methods) to control cell therapy products and/or tissue-engineered products and/or tissues and organs used for human transplantation in a research and development environment

DIA Working party (Dialysis)

Terms of reference

- Drafting and revision of texts in the field of preparations for dialysis

Profile for experts

- Current expertise in the field of preparations for dialysis
- Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs
- Several years of experience in one or more of the following fields:
Quality control of preparations for dialysis in a pharmaceutical manufacturing setting or in a hospital

Quality control of preparations for dialysis in a regulatory authority

Assessment of the relevant parts of applications for marketing authorisation within a medicines agency

Quality control of preparations for dialysis in an independent testing laboratory

Method development and verification in a regulatory authority

EXP Working Party (Excipient performance)

Terms of reference

• Drafting and maintaining the FRC (Functionality Related Characteristics) sections of monographs on excipients to reflect current best practices, in consultation with the appropriate Groups of Experts or Working Parties of the Ph. Eur.

• Review, where necessary, and maintenance of general chapter 5.15 FRCs of excipients to align it with current regulatory guidance (e.g. ICH Q8 guideline)

• Drafting and maintenance of the text on Co-processed excipients

• Review pharmacopoeial and other regulatory texts on general information on excipients with a view to proposing necessary additions and updates, where relevant

Profile for experts

• Current expertise in analytical methods (especially those included in the Ph. Eur. section 2.9. Pharmaceutical technical procedures), related to control of excipients and in development of control methods

• Several years of experience in one or more of the following fields:
  o Quality control of excipients in a bulk or pharmaceutical manufacturing setting
  o Pharmaceutical and excipient research and development
  o Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  o Development of control methods for excipients, comprising methods to determine excipient performance (FRCs) in a research and development environment
  o Pharmaceutical quality control in an independent testing laboratory

EXT Working Party (Extracts)

Terms of reference

• Revision of the general monograph on Extracts (0765) with the aim of clarifying/improving the definitions and requirements of the different types of extracts whilst maintaining the established classification system of extracts

Profile for experts

• Several years of experience in one or more of the following fields:
  o Assessment of the relevant parts of applications for marketing authorisation of herbal medicinal products within a medicines agency
  o Production or quality control of extracts for further use in herbal medicinal products
  o Production or quality control of herbal medicinal products containing extracts

GEL Working Party (Gelatin)

Terms of reference

• To provide support and advice in case of questions raised by e.g. users in the field of gelatin

• International harmonisation of monographs on Gelatin
Profile for experts:

- Current expertise in pharmaceutical analytical methods, related to quality control of gelatin and in development of control methods
- Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of test methods and drafting of texts.
- Several years of experience in one or more of the following fields:
  - Quality control in a pharmaceutical or bulk manufacturing setting (gelatin or use of gelatin)
  - Market surveillance of quality in a regulatory authority
  - Pharmaceutical quality control in an independent testing laboratory
  - Method development and verification in a regulatory authority
  - Development of pharmaceutical control methods using near infrared spectrometry for gelatin identification

GLS Working Party (Glass Containers)

Terms of reference

- Drafting and revision of texts in the field of glass containers

Profile for experts

- Current expertise in the production of glass containers, analytical methods, related to quality control of glass containers and in development of control methods
- Access to laboratory facilities for verification and validation of methods proposed for inclusion in general chapters
- Several years of experience in one or more of the following fields:
  - Quality control in a pharmaceutical manufacturing setting for control of glass containers
  - Production and/or Quality control of glass containers in an industrial setting
  - Market surveillance of quality in a regulatory authority
  - Pharmaceutical quality control in an independent testing laboratory
  - Development of control methods for control of glass containers in a research and development environment

GTP Working Party (Gene Therapy Products)

Terms of reference

- Revision of the general chapter 5.14 Gene transfer medicinal products for human use (raw materials part) to account for the chapter 5.2.12 Raw materials of biological origin for the production of cell-based and gene therapy medicinal products; Evaluation of the general chapter 5.14 in the view of development in the field within last decade and its potential revision
- Participation in elaboration/revision of transversal texts elaborated by other Groups of Experts or Working Parties, (e.g. general chapter 2.6.35 Quantification and characterisation of residual host cell DNA)
- Drafting and revision of other texts in the field of gene therapy

Profile for experts

- Current expertise in analytical methods related to development and quality control of gene therapy products and in development of control methods
- Several years of experience in one or more of the following fields:
  - Development of gene therapy products
  - Quality control of gene therapy products in a pharmaceutical manufacturing setting or in a hospital environment
  - Assessment of applications for marketing authorisation of gene therapy products
  - Marketing surveillance of quality in a regulatory authority
HM Working Party (Heavy metals)

Terms of reference

- Drafting and revision of the general chapter 5.20 Elemental impurities. In this context, identification of technical issues which need to be addressed by ICP working party such as sample preparation and instrumental determination by atomic emission spectrometry, inductively coupled plasma - atomic emission spectrometry and inductively coupled plasma - mass spectrometry and which would require an update of the respective general methods
- International harmonisation of chapter 2.4.20 (PDG item G-07)

Profile for experts

- Up-to-date substantial expertise in pharmaceutical analytical methods, related to quality control of active substances and excipients allowing a holistic view on the occurrence of metals from either synthesis or contamination
- Several years of experience in one or more of the following fields:
  - Quality control in a pharmaceutical manufacturing setting
  - Quality control of synthetic and semi-synthetic organic products in a bulk manufacturing setting
  - Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  - Pharmaceutical quality control of active substances and /or excipients in an independent testing laboratory specialised in testing for metals as residues from synthesis or contaminants

HMM Working Party (Homoeopathic Manufacturing Methods)

Terms of reference

- Drafting and revision of monographs in the field of homoeopathic manufacturing methods

Profile for experts

- Knowledge of currently used homoeopathic manufacturing methods
- Several years of experience in one or more of the following fields:
  - Assessment of application for marketing authorisation of homoeopathic products within a medicines agency or equivalent
- Industry representatives are normally not appointed to the HMM Working Party. They may be invited to contribute to elaboration of monographs during hearings organised on a case-by-case basis by the Secretariat

HOM Working Party (Homoeopathic Raw Materials and Stocks)

Terms of reference

- Drafting and revision of texts in the field of homoeopathic raw materials and stocks

Profile for experts

- Current expertise in pharmaceutical analytical methods, related to quality control of homoeopathic raw materials and stocks and in development of control methods
- Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of test methods and drafting of texts
- Several years of experience in one or more of the following fields:
Quality control of homoeopathic raw materials and stocks in a pharmaceutical manufacturing setting

Assessment of applications for marketing authorisation of homoeopathic products within an agency

Quality control of homoeopathic raw materials and stocks in an independent testing laboratory

Development of methods for control of homoeopathic raw materials and stocks in a research and development environment

Method development, and verification in a regulatory authority

ICP Working Party (Inductively-Coupled Plasma)

Terms of reference

- Drafting and revision of texts in the field of atomic absorption spectrometry, atomic emission spectrometry, inductively coupled plasma - atomic emission spectrometry and inductively coupled plasma - mass spectrometry

Profile for experts

- Current expertise in the development, and application of analytical procedures involving the above mentioned techniques
- Several years of experience in one or more of the following fields:
  - Quality control of herbal drugs, herbal drug preparations, synthetic, semi-synthetic, natural origin, biological or biotechnological products in a pharmaceutical setting
  - Quality control in a regulatory authority or an independent testing laboratory

INH Working Party (Inhalations)

Terms of reference

- Drafting and revision of monographs and general chapters in the field of preparations for inhalation
- International harmonisation of related general chapters

Profile for experts

- Current expertise in pharmaceutical analytical methods, related to quality control of preparations for inhalation and in development of control methods
- Several years of experience in one or more of the following fields:
  - Quality control of preparations for inhalation in a pharmaceutical manufacturing setting
  - Market surveillance of quality in a regulatory authority
  - Assessment of applications for marketing authorisation of preparations for inhalation within an agency
  - Development of control methods for control of preparations for inhalation in a research and development environment
  - Pharmaceutical quality control in an independent testing laboratory
  - Method development and verification in a regulatory authority

LEC Working Party (Lecithins)

Terms of reference

- Drafting and revision of monographs in the field of lecithins

Profile for experts

- Current expertise in pharmaceutical analytical methods, related to quality control of lecithins and in development of control methods
- Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of test methods and drafting of texts/
- Several years of experience in one or more of the following fields:
Quality control of lecithins in a pharmaceutical or bulk manufacturing setting
Market surveillance of quality in a regulatory authority
Pharmaceutical quality control in an independent testing laboratory
Development of control methods for lecithins in a research and development environment
Method development and verification in a regulatory authority

MAB Working Party (Monoclonal Antibodies)

Terms of reference:
- To undertake a pilot phase to elaborate general methods for analysis of monoclonal antibodies and individual monographs using the multisource approach (according to document PA/PH/Exp. MAB/T(14) 1)
- Drafting and revision of texts in the field of monoclonal antibodies

Profile for experts
- Current expertise in pharmaceutical analytical methods, related to quality control of monoclonal antibodies and in development of control methods
- Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs or access to licensing files. Essential: Active involvement in laboratory verification of test methods and drafting of texts
- Several years of experience in one or more of the following fields:
  - Quality control of monoclonal antibodies in a pharmaceutical manufacturing setting
  - Market surveillance of quality in a regulatory authority
  - Assessment of applications for marketing authorisation of monoclonal antibodies within an agency
  - Development of control methods for control of monoclonal antibodies in a research and development environment
  - Pharmaceutical quality control in an independent testing laboratory

MG Working Party (General methods)

Terms of reference
- Drafting and revision of general chapters, particularly in the field of chemical and physico-chemical analysis.
- If needed, requests the nomination of ad hoc specialists to create sub-groups for specific general chapters on the work programme, and management of the activities for the elaboration or revision of these general chapters within the sub-groups.
- Co-operation with other groups of experts and working parties which are in charge of elaboration and revision of general chapters where relevant.
- Maintenance of template for general methods

Profile for experts
- Members of a regulatory authority, universities or the pharmaceutical/chemical industries
- Current expertise and extensive knowledge in pharmacopoeial methods and/or instruments used in the quality control of active substances, excipients and/or medicinal products and in development of control methods
- Several years of experience in one or more of the following fields:
  - Method development and verification in e.g. analytical or pharmaceutical development, a regulatory authority, or testing laboratory
  - Quality control of active substances, excipients and/or medicinal products
  - Market surveillance of quality of medicinal products in a regulatory authority
  - Assessment of the relevant parts of applications for marketing authorisation within a medicines
agency

**MYC Working Party (Mycoplasma)**

Terms of reference

- Revision of general chapter 2.6.7 *Mycoplasmas* in order to update it with the current practices in the field of mycoplasma testing

Profile for experts

- Current expertise in mycoplasma testing of medicinal products and in development of control methods
- Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs,
- Several years of experience in one or more of the following fields:
  - Mycoplasma testing in a pharmaceutical manufacturing setting
  - Mycoplasma testing in an official control laboratory for medicines
  - Mycoplasma testing in an independent testing laboratory
  - Development of test methods for mycoplasmas in a research and development environment

**NBC Working Party (Non-Biological Complex Drugs)**

Terms of reference

- Elaboration and revision of monographs on non-biological complex drugs (e.g. nanoparticle dispersions, like for example iron sucrose concentrated solution)

Profile for experts

- Current expertise in the development and/or quality control of non-biological complex drugs and in development of control methods
- Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs,
  **Essential:** Active involvement in laboratory verification of test methods and drafting of texts and
- Several years of experience in one or more of the following fields:
  - Quality control in a pharmaceutical manufacturing setting or in an independent testing laboratory (e.g. Market surveillance of quality in a regulatory authority)
  - Pharmaceutical and/or analytical development related to respective formulations
  - Assessment of the relevant parts of applications for marketing authorisation within a medicines agency

**P4BIO Working Party (P4 Bio)**

Terms of reference

- Drafting and revision of monographs in the field of single-source biologicals

Profile for experts

- Group P4Bio is restricted to regulators from Ph. Eur. Member states however industry representatives may be invited to contribute by submission of data and interaction with the group via the Secretariat
- Current expertise in pharmaceutical analytical methods, related to quality control of biologicals and in development of control methods
- Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs or access to licensing files (essentially originating from CAP), **Essential:** Active involvement in laboratory verification of test methods and drafting of texts and
- Several years of experience in one or more of the following fields:
  - Quality control in a regulatory authority
  - Assessment of the relevant parts (biologicals) of applications for marketing authorisation
  - Market surveillance of quality in a regulatory authority
PA Working Party (Pyrrolizidine alkaloids)

Terms of reference

• Drafting of a general chapter allocated to the group by the Commission in the field of pyrrolizidine alkaloids.
• Maintenance of the list of PA alkaloids which may be covered by the general chapter on PA alkaloids.

Profile for experts

• Current expertise in PA analysis, related to quality control of herbal drugs and in development of control methods.
• Access to laboratory facilities for quality control. Essential: active involvement in laboratory verification of methods and drafting of texts.
• Several years of experience in one or more of the following fields:
  o Quality control of herbals in a pharmaceutical or bulk manufacturing setting, in a regulatory authority or in any other specialised testing laboratory;
  o Development and/or lab verification of control methods for analysis of pyrrolizidine alkaloids in a research and development environment or in a regulatory authority.

PaedF Working Party (European Paediatric Formulary)

Terms of reference

• Elaboration, and revision of monographs on paediatric preparations according to criteria and guidelines approved by the CD-P-PH.
• Establishment and maintenance of a Technical Guide for the elaboration and maintenance of monographs on paediatric preparations.

Profile for experts

• Current expertise in development of paediatric preparations (including toxicologists).
• Current expertise in analytical methods related to quality control of ingredients (APIs and excipients) and preparations and in the development of such methods; Access to laboratory facilities for verification of methods proposed for inclusion in monographs.
• Current expertise in clinical/pharmacological treatment of several paediatric age groups.
• Several years of experience in one or more of the following fields:
  o Pharmaceutical development and/or manufacturing of paediatric preparations (in a community or hospital pharmacy, research unit, or in pharmaceutical industry);
  o Method development and verification of medicinal preparations in a pharmaceutical manufacturing setting (including research and development), in a regulatory authority, in a community or hospital pharmacy or in an independent testing laboratory;
  o Market surveillance of quality in a regulatory authority.
  o Assessment of the relevant parts of applications for marketing authorisation of paediatric medicinal products (including safety assessment);
  o Elaboration/assessment of monographs for national paediatric formularies.
  o Clinical/pharmacological treatment of children belonging to several age groups.

PAT Working Party (Process Analytical Technology)

Terms of reference

• Review and revision of existing general monographs and chapters of existing pharmacopoeial texts in view of needs arising from Process Analytical Technology (PAT), Continuous Manufacturing (CM), Real Time release testing (RTRT) or Quality by Design (QbD) concepts.
• Identify and discuss the implication of the above mentioned concepts on the texts of European Pharmacopoeia and make proposals to the Commission where needed.
• Support and advise other group of experts and working parties where elements of the above mentioned concepts are concerned.
Profile for experts

- Expertise in chemical or pharmaceutical development and control methods applied during manufacture and to active substances or finished pharmaceutical preparations
- Several years of experience in one or more of the following fields:
  - Development of pharmaceutical preparations using PAT, CM, RTRT or QbD concepts in an industrial setting
  - Assessment of the relevant parts of applications for marketing authorisation containing PAT, CM, RTRT or QbD concepts within a medicines agency
  - Development of control strategies including PAT, CM, RTRT or QbD concepts approaches for testing of active substances or pharmaceutical preparations
  - Development of pharmaceutical preparations using modelling and chemometrics associated with the analytical aspects for PAT

POW Working Party (Powder Characterisation)

Terms of reference

- Drafting and revision of general chapters in the field of powder characterisation
- International harmonisation of general chapters

Profile for experts

- Current expertise in methods for powder characterisation, related to quality control of active substances and excipients and in development of control methods
- Several years of experience in one or more of the following fields:
  - Quality control of active substances and excipients in a pharmaceutical manufacturing setting
  - Assessment of the relevant parts of applications for marketing authorisation
  - Market surveillance of quality in a regulatory authority
  - Development of methods for characterisation of powders in a research and development environment
  - Pharmaceutical quality control in an independent testing laboratory

PRP Working Party (Precursors for Radiopharmaceutical Preparations)

Terms of reference

- Drafting and revision of texts in the field of non-radioactive precursors for radiopharmaceutical preparations

Profile for experts

- Expertise in chemical, pharmaceutical and radiopharmaceutical methods, related to quality control of radiopharmaceutical preparations and their precursors
- Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs. Essential: Active involvement in laboratory verification of test methods and drafting of texts
- Several years of experience in one or more of the following fields:
  - Quality control of radiopharmaceutical preparations and their precursors
  - Quality control of synthetic organic and/or inorganic products in a chemical or pharmaceutical setting
  - Quality control in an independent testing laboratory
  - Development of analytical procedures for the control of radiopharmaceutical preparations and their precursors

PST Working Party (Pesticide Residues)

Terms of reference

- Drafting and revision of texts in the field of pesticide residues
Advising the Commission on acceptance criteria for pesticide residues to be included in monographs

Maintenance of the list of pesticides tabled in general chapter on pesticide residues

Profile for experts

- Current expertise in pesticide analysis, related to quality control of active substances and excipients and in development of control methods
- Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs
- Several years of experience in one or more of the following fields:
  - Quality control for pesticide residues in herbals in a pharmaceutical or bulk manufacturing setting
  - Market surveillance of quality in a regulatory authority
  - Pharmaceutical quality control in an independent testing laboratory
  - Development of control methods for analysis of pesticide residues in a research and development environment

SDA Working Party (Spectroscopy and Data Analysis)

Terms of reference

- Drafting and revision of general chapters in the fields of:
  - Measurement techniques relying on spectroscopy, with the exception of specific spectroscopic techniques where the drafting and revision of general chapters is allocated to other, more specialised groups of experts and working parties.
  - Chemical imaging techniques, e.g. spectral and multispectral imaging, electron microscopy, field effect and atomic force microscopies, optical and X-ray tomography, etc.
  - Chemometrics and data sciences techniques relying on multivariate data analysis, numerical methods, algorithmics, data modelling, data mining, artificial intelligence, etc., and image analysis techniques.
- to support and advise other group of experts and working parties where elements of the above mentioned measurement and data analysis techniques are concerned and where relevant.

Profile for experts

- Current expertise in spectroscopy related to quality control of active substances, excipients or products, in development of analytical control methods.
- Ideally, access to laboratory facilities for verification and validation of methods proposed for inclusion in general chapters and monographs. Essential: Active involvement in laboratory verification of test methods and drafting of texts Several years of experience in one or more of the following fields:
  - Use of spectroscopic techniques for pharmaceutical quality control in a pharmaceutical manufacturing setting, a regulatory authority or an independent testing laboratory.
  - Development of pharmaceutical in-, on-, or at-line control methods using spectroscopic or imaging techniques or chemometrics and data analysis, in a research and development environment.
  - Assessment of applications for marketing authorisation.
  - Use of spectroscopic techniques for the market surveillance of the quality of pharmaceutical substances or products.

SIT Working Party (Second identification test)

Terms of reference

- To support and advise the Commission, Groups of Experts or Working Parties on revision/suppression of existing identification series, notably arising from the REACH regulation, where relevant.
- Propose to the Commission further items for the work programme (such as replacements of methods not in line with the available instrumentation in pharmacies or monographs with missing second identification)
Profile for experts

- Pharmacists regularly involved in preparation of extemporaneous or stock preparation of medicinal products in community pharmacies or hospitals as well as in the analysis of the pharmaceutical substances used
- Pharmacists or chemists with special interest/expertise in analytical methods commonly available in pharmacies
- Members of a regulatory authority

ST Working Party (Standard Terms)

Terms of reference

- Development of standard terms and definitions for the Standard Terms database for dosage forms, units of presentation, routes of administration, packaging and related terms at the request of Competent authorities of Member States and certain non-member states (e.g. competent authority members of ICH), the European Commission or the EMA.

Profile for experts

- Current expertise in pharmaceutical dosage forms
- Several years of experience in one or more of the following fields:
  - Assessment of the pharmaceutical development part of applications for authorisation of medicinal products
  - Development of general monographs for dosage forms (group of experts or national pharmacopoeia secretariat)
  - Experience in formulation of medicinal products
- Members of the working party may be from a regulatory authority, universities

SUT Working Party (Sutures)

Terms of reference

- Drafting and revision of texts in the field of sutures

Profile for experts

- Expertise in pharmaceutical analytical methods, related to quality control of sutures and in development of control methods
- Several years of experience in one or more of the following fields:
  - Quality control of sutures
  - Development of methods for control of sutures

TCM Working Party (Traditional Chinese Medicines)

Terms of reference

- Drafting and revision of texts in the field of herbal drugs and herbal drug preparations preferably based on the principle of adapting/improving existing monographs or methods to control herbal drugs used in Traditional Chinese Medicines (TCM)
- Drafting general chapters related to the specific needs of TCM herbal drugs

Profile for experts

- Current expertise in pharmaceutical analytical methods, related to quality control of herbal drugs and herbal drug preparations and in development of control methods
- Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs
- Several years of experience in one or more of the following fields:
  - Quality control of herbal drugs/herbal drug preparations in a manufacturing setting
  - Pharmaceutical quality control of herbal drugs and herbal drug preparations in an independent testing laboratory
PA/PH/SG (19) 35

1. Development of methods for control of herbal drugs
2. Involvement in market surveillance or regulatory oversight of imported TCM herbal drugs
3. **Essential**: Active involvement in laboratory verification of test methods for TCM herbal drugs and in drafting of texts.
4. Development of chromatographic separation systems for herbal drug constituents
5. Knowledge in cultivation, harvesting, processing and use of TCM herbal drugs

**VIT Working Party (Vitamins)**

**Terms of reference**

- Drafting and revision of monographs in the field of vitamins and vitamin derivatives

**Profile for experts**

- Current expertise in pharmaceutical analytical methods, related to quality control of vitamins and excipients and in development of control methods. *The need of a specialist for vitamin D type substances is highlighted*
- Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs, **Essential**: Active involvement in laboratory verification of test methods and drafting of texts.
- Several years of experience in one or more of the following fields:
  1. Quality control of vitamins in a pharmaceutical or bulk manufacturing setting
  2. Market surveillance of quality in an official control laboratory for medicines
  3. Pharmaceutical quality control in an independent testing laboratory
  4. Development of methods for control of vitamins in a research and development environment
  5. Method development and verification in a national pharmacopoeia laboratory

**WAT Working Party (Water)**

**Terms of reference**

- Drafting and revision of texts in the field of water
- International harmonisation of relevant texts

**Profile for experts**

- Current expertise in analytical methods applicable in water analysis in development of control methods
- Several years of experience in one or more of the following fields:
  1. Quality control of water in a pharmaceutical manufacturing setting
  2. Inspection of manufacturing sites
  3. Pharmaceutical quality control in an independent testing laboratory
  4. Development of methods for control of pharmaceutical waters in a research and development environment